Health Benefits In 2025: Family Premiums Rise 6 Percent, Large Employers Increase Coverage Of GLP-1s For Weight Loss

In 2025, the average annual premium for family health coverage reached $26,993, an increase of $1,408 (6 percent) from the previous year. Covered workers contributed an average of 16 percent ($1,440) toward premiums to enroll in single coverage and 26 percent ($6,850) for family coverage. Among work...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health affairs (Millwood, Va.) Jg. 44; H. 11; S. 1359
Hauptverfasser: Claxton, Gary, Rae, Matthew, Damico, Anthony, Winger, Aubrey, Wager, Emma
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.11.2025
Schlagworte:
Cost Sharing - economics
Deductibles and Coinsurance - economics
Glucagon-Like Peptide 1 - agonists
Glucagon-Like Peptide 1 - economics
Health Benefit Plans, Employee - economics
Health Benefit Plans, Employee - statistics & numerical data
Health Benefit Plans, Employee - trends
Health Expenditures
Humans
Insurance Coverage - economics
Insurance Coverage - statistics & numerical data
Insurance Coverage - trends
United States
Weight Loss - drug effects
United States
ISSN:2694-233X, 2694-233X
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In 2025, the average annual premium for family health coverage reached $26,993, an increase of $1,408 (6 percent) from the previous year. Covered workers contributed an average of 16 percent ($1,440) toward premiums to enroll in single coverage and 26 percent ($6,850) for family coverage. Among workers with a general annual deductible for single coverage, the average deductible was $1,886. Nearly one in five (19 percent) large firms offering health benefits covered GLP-1 agonists when used primarily for weight loss. Many employers reported concern about out-of-pocket spending: 45 percent of firms offering health benefits indicated that their employees had a "high" or "moderate" level of concern about the affordability of cost sharing. Thirty-six percent of large firms offering health benefits reported that prescription drug prices contributed "a great deal" toward premium increases.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2694-233X
2694-233X
DOI:10.1377/hlthaff.2025.01106